BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 16620696)

  • 1. Incidence and causes of inappropriate detection and therapy by implantable defibrillators of cardioversion in patients with ventricular tachyarrhythmia.
    Chen RH; Chen KP; Wang FZ; Hua W; Chen X; Zhang S
    Chin Med J (Engl); 2006 Apr; 119(7):557-63. PubMed ID: 16620696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.
    Korte T; Köditz H; Niehaus M; Paul T; Tebbenjohanns J
    Pacing Clin Electrophysiol; 2004 Jul; 27(7):924-32. PubMed ID: 15271011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Implantable cardioverter-defibrillators in the prevention of sudden cardiac death].
    Kozák M; Krivan L; Semrád B
    Vnitr Lek; 2001 Jun; 47(6):361-70. PubMed ID: 11494881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inadequate therapies with implantable cardioverter-defibrillators--incidence, etiology, predictive factors and preventive strategies].
    Weber M; Block M; Brunn J; Bänsch D; Böcker D; Hammel D; Gietzen F; Breithardt G
    Z Kardiol; 1996 Nov; 85(11):809-19. PubMed ID: 9064943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Implantable cardioverter-defibrillators in patients resuscitated from sudden death and in patients with sustained refractory ventricular tachycardia].
    Adragão P; Parreira L; Neves J; Morgado F; Abecassis M; Almeida M; Martins D; Bonhorst D; Seabra-Gomes R
    Rev Port Cardiol; 1996 Mar; 15(3):195-206, 179, 181. PubMed ID: 8634168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inappropriate shocks in patients receiving internal cardioverter-defibrillators for malignant ventricular arrhythmias.
    Prasad K; Kishore AG; Anderson MH; Ward DE; Rowland E; Gill JS; Camm AJ
    Indian Heart J; 1997; 49(4):403-7. PubMed ID: 9358664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
    Wilkoff BL; Hess M; Young J; Abraham WT
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.
    Sweeney MO; Wathen MS; Volosin K; Abdalla I; DeGroot PJ; Otterness MF; Stark AJ
    Circulation; 2005 Jun; 111(22):2898-905. PubMed ID: 15927965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy.
    Bhavnani SP; Coleman CI; White CM; Clyne CA; Yarlagadda R; Guertin D; Kluger J
    Europace; 2008 Jul; 10(7):854-9. PubMed ID: 18495672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
    Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
    J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results.
    Wathen MS; DeGroot PJ; Sweeney MO; Stark AJ; Otterness MF; Adkisson WO; Canby RC; Khalighi K; Machado C; Rubenstein DS; Volosin KJ;
    Circulation; 2004 Oct; 110(17):2591-6. PubMed ID: 15492306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The implantable cardioverter-defibrillator: the Portuguese experience].
    Adragão P; Neves J; Sousa J; Fançoni J; da Silva N; Antunes E; Elvas L; Bernardo J
    Rev Port Cardiol; 1997 Apr; 16(4):367-74, 351-2. PubMed ID: 9254126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter defribrillator shocks: a troubleshooting guide.
    Swerdlow CD; Zhang J
    Rev Cardiovasc Med; 2001; 2(2):61-72. PubMed ID: 12439383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
    Corrado D; Calkins H; Link MS; Leoni L; Favale S; Bevilacqua M; Basso C; Ward D; Boriani G; Ricci R; Piccini JP; Dalal D; Santini M; Buja G; Iliceto S; Estes NA; Wichter T; McKenna WJ; Thiene G; Marcus FI
    Circulation; 2010 Sep; 122(12):1144-52. PubMed ID: 20823389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular tachycardia.
    Glikson M; Lipchenca I; Viskin S; Ballman KV; Trusty JM; Gurevitz OT; Luria DM; Eldar M; Hammill SC; Friedman PA
    J Cardiovasc Electrophysiol; 2004 Jun; 15(6):658-64. PubMed ID: 15175060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.